Timing of first-line cancer treatments - early versus late - a systematic review of phase III randomized trials.

Abstract:

PURPOSE:To conduct a systematic review and meta-analysis of all phase III randomized controlled trials comparing efficacy of early versus late first-line or initial treatments for cancer. METHODS:A comprehensive literature search of MEDLINE and Cochrane library databases was performed (1966-2008). Data was extracted and pooled as per the methods recommended by the Cochrane Collaboration. RESULTS:Of the 570 identified studies, 10 (3811 patients) met inclusion criteria: three each in prostate cancer and multiple myeloma (MM), two in chronic lymphocytic leukemia (CLL), and one each in lung cancer, and follicular lymphoma. The analyses showed no survival benefit with early treatment except in prostate cancer (hazard ratio [HR]=1.23, 95% CI 1.11-1.37 p<0.001). There was no survival difference in MM (HR=0.92, 95% CI 0.56-1.52 p=0.74), CLL (HR=0.76, 95% CI 0.56-1.04 p=0.09), lung cancer (HR=0.95, 95% CI 0.72-1.24 p=0.71), or follicular lymphoma (HR=1, 95% CI 0.55-1.83 p=0.99). No statistically significant difference in response rate between early and late treatment was detected in any cancer type. CONCLUSIONS:Data shows that delaying cancer treatments does not necessarily compromise therapeutic outcomes except possibly in locally advanced prostate cancer. These findings provide a unique window to oncologists and patients to address time-sensitive issues if desired by patients.

journal_name

Cancer Treat Rev

journal_title

Cancer treatment reviews

authors

Mhaskar AR,Quinn G,Vadaparampil S,Djulbegovic B,Gwede CK,Kumar A

doi

10.1016/j.ctrv.2010.04.001

subject

Has Abstract

pub_date

2010-12-01 00:00:00

pages

621-8

issue

8

eissn

0305-7372

issn

1532-1967

pii

S0305-7372(10)00078-2

journal_volume

36

pub_type

杂志文章,meta分析,评审
  • Stereotactic radiosurgery and hypofractionated stereotactic radiotherapy: normal tissue dose constraints of the central nervous system.

    abstract::Single-fraction stereotactic radiosurgery (SRS) and hypofractionated stereotactic radiotherapy (SRT) are radiation planning and delivery techniques used for the treatment of intracranial and spine/spinal cord tumors and targets. For cranial SRS and SRT, critical normal tissues/structures include the brainstem, cranial...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.04.004

    authors: Milano MT,Usuki KY,Walter KA,Clark D,Schell MC

    更新日期:2011-11-01 00:00:00

  • The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target.

    abstract::Gastric cancer (GC) represents the fifth cause of cancer-related death worldwide. Molecular biology has become a central area of research in GC and there are currently at least three major classifications available to elucidate the mechanisms that drive GC oncogenesis. Further, tumor microenvironment seems to play a c...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2020.102015

    authors: Gambardella V,Castillo J,Tarazona N,Gimeno-Valiente F,Martínez-Ciarpaglini C,Cabeza-Segura M,Roselló S,Roda D,Huerta M,Cervantes A,Fleitas T

    更新日期:2020-06-01 00:00:00

  • Current management of stage IV nasopharyngeal carcinoma without distant metastasis.

    abstract::Up to one in four patients with nasopharyngeal carcinoma present with non-metastatic stage IV disease (i.e. T4 or N3). Distinct failure patterns exist, despite the routine adoption of contemporary treatment modalities such as intensity modulated radiotherapy and systemic chemotherapy. Concurrent chemoradiotherapy (CCR...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2020.101995

    authors: Ng WT,Corry J,Langendijk JA,Lee AWM,Mäkitie A,Mendenhall WM,Rinaldo A,Rodrigo JP,Saba NF,Smee R,Strojan P,Suárez C,Vermorken JB,Ferlito A

    更新日期:2020-04-01 00:00:00

  • Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review.

    abstract:PURPOSE:To evaluate the existing evidence regarding the long-term risk of cardiovascular disease (CVD) after radiotherapy for childhood cancer. PATIENTS AND METHODS:MEDLINE and EMBASE were searched for articles reporting on radiation-induced CVD after childhood cancer published between 1966 and October 2002. Informati...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2005.03.008

    authors: van der Pal HJ,van Dalen EC,Kremer LC,Bakker PJ,van Leeuwen FE

    更新日期:2005-05-01 00:00:00

  • The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.

    abstract::Dysregulated activation of the MET tyrosine kinase receptor is implicated in the development of solid tumors and can arise through several mechanisms, including gene amplification, overexpression of the receptor and/or its ligand hepatocyte growth factor (HGF), and the acquisition of activating mutations. The most com...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2020.102022

    authors: Salgia R,Sattler M,Scheele J,Stroh C,Felip E

    更新日期:2020-07-01 00:00:00

  • Neoadjuvant endocrine therapy in breast cancer.

    abstract::The use of endocrine therapy is well established as a primary treatment for locally advanced breast cancer. However, despite the current popularity of neoadjuvant chemotherapy for operable tumours, there is relatively little published evidence for pre-operative endocrine therapy in operable disease, particularly outsi...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2006.10.003

    authors: Beresford MJ,Ravichandran D,Makris A

    更新日期:2007-02-01 00:00:00

  • AR-V7 and prostate cancer: The watershed for treatment selection?

    abstract::The androgen receptor (AR) plays a key role in progression to metastatic castration-resistant prostate cancer (mCRPC). Despite the recent progress in targeting persistent AR activity with the next-generation hormonal therapies (abiraterone acetate and enzalutamide), resistance to these agents limits therapeutic effica...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.12.003

    authors: Ciccarese C,Santoni M,Brunelli M,Buti S,Modena A,Nabissi M,Artibani W,Martignoni G,Montironi R,Tortora G,Massari F

    更新日期:2016-02-01 00:00:00

  • Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.

    abstract::Neoadjuvant chemotherapy (NAC) for breast cancer is evolving and subsequent adjuvant systemic treatment is mainly based on the presence of the Estrogen (ER) receptor, Progesterone (PR) receptor and Human Epidermal growth factor Receptor 2 (HER2) status on the core needle biopsy prior to treatment. It is not well known...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.11.006

    authors: van de Ven S,Smit VT,Dekker TJ,Nortier JW,Kroep JR

    更新日期:2011-10-01 00:00:00

  • Intraperitoneal chemotherapy in ovarian cancer.

    abstract::From a theoretical viewpoint, intraperitoneal therapy (IP) in patients with ovarian cancer, a malignancy which remains mainly confined to the peritoneal cavity, is logical. Over the past decades this approach has evolved into a therapeutic strategy for a selected group of patients. Data available at present suggest a ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1053/ctrv.1999.0152

    authors: Hofstra LS,de Vries EG,Mulder NH,Willemse PH

    更新日期:2000-04-01 00:00:00

  • Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms.

    abstract::Targeted therapies have unique toxicity profiles. Common adverse events include rash, diarrhea, hypertension, hypothyroidism, proteinuria, depigmentation, and hepatotoxicity. Some of these toxicities are caused by on-target, mechanism-associated effects, which can be stratified as to whether or not the targets are rel...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.05.003

    authors: Liu S,Kurzrock R

    更新日期:2014-08-01 00:00:00

  • Pediatric sarcomas and related tumors of the head and neck.

    abstract::Sarcomas of the head and neck region are a rare group of tumors in children and present challenges with regard to evaluation and treatment. Rhabdomyosarcomas are the most common sarcomas of the head and neck in children. Presence of metastases and complete surgical resectability continue to be the most relevant clinic...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.04.005

    authors: Huh WW,Fitzgerald N,Mahajan A,Sturgis EM,Beverly Raney R,Anderson PM

    更新日期:2011-10-01 00:00:00

  • Fertility issues in survivors from adolescent cancers.

    abstract::Infertility is a common and distressing late-effect of cancer treatment. Whist sperm banking for post-pubertal males and embryo freezing for women (who are in a stable relationship at the time of treatment) are highly successful fertility preservation strategies, for females without a partner (including young and pre-...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2007.02.001

    authors: Pacey AA

    更新日期:2007-11-01 00:00:00

  • How did lomustine become standard of care in recurrent glioblastoma?

    abstract::Glioblastomas are the most common malignant primary intrinsic brain tumors. Their incidence increases with age, and males are more often affected. First-line management includes maximum safe surgical resection followed by involved-field radiotherapy plus concomitant and six cycles of maintenance temozolomide chemother...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2020.102029

    authors: Weller M,Le Rhun E

    更新日期:2020-07-01 00:00:00

  • Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.

    abstract::Triple-negative breast cancer (TNBC) accounts for ∼10-20% of breast cancers and is associated with relatively poor prognosis, earlier disease recurrence and higher number of visceral metastases. Despite an increasing understanding of the molecular heterogeneity of TNBC, clinical trials of targeted agents have thus far...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.09.004

    authors: Schettini F,Giuliano M,De Placido S,Arpino G

    更新日期:2016-11-01 00:00:00

  • Targeted therapeutic approaches for hormone-refractory prostate cancer.

    abstract::Prostate cancer is one of the leading causes of cancer related death in men, and remains incurable in the metastatic setting. Despite the initial response to androgen deprivation, the disease gradually progresses to a hormone-refractory state due to cumulative genetic alterations in tumour cells or the microenvironmen...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.06.001

    authors: Stavridi F,Karapanagiotou EM,Syrigos KN

    更新日期:2010-04-01 00:00:00

  • Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.

    abstract::Patients with solid tumours are at risk of impaired bone health from metastases and cancer therapy-induced bone loss (CTIBL). We review medical management of bone health in patients with solid tumours over the past 30 years, from first-generation bisphosphonates to the receptor activator of nuclear factor κB ligand (R...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2019.05.003

    authors: von Moos R,Costa L,Gonzalez-Suarez E,Terpos E,Niepel D,Body JJ

    更新日期:2019-06-01 00:00:00

  • Novel therapeutic approaches to the treatment of metastatic breast cancer.

    abstract::Metastatic breast cancer is ultimately an incurable disease, although recent data have shown that its incidence is decreasing and that patients with metastatic breast cancer live longer. This improvement in survival seems to be linked with the introduction of new therapeutic agents, novel combinations of existing ther...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.10.001

    authors: Fernández Y,Cueva J,Palomo AG,Ramos M,de Juan A,Calvo L,García-Mata J,García-Teijido P,Peláez I,García-Estévez L

    更新日期:2010-02-01 00:00:00

  • Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: how should we counsel cancer patients about breastfeeding?

    abstract::An increasing number of women are diagnosed with cancer during pregnancy and lactation. Women are usually advised to interrupt breastfeeding during systemic anticancer treatment for fear of serious adverse effects to the nursed infant. However, the issue is poorly addressed in the literature and very few studies have ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.10.002

    authors: Pistilli B,Bellettini G,Giovannetti E,Codacci-Pisanelli G,Azim HA Jr,Benedetti G,Sarno MA,Peccatori FA

    更新日期:2013-05-01 00:00:00

  • Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer.

    abstract::The majority of stage III NSCLC patients managed with a combination of radiotherapy and chemotherapy will develop a locoregional or distant relapse. Concomitant radiochemotherapy allows for improved local control but has no impact on extrathoracic recurrences. To ameliorate this inefficiency the concept of consolidati...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.04.001

    authors: Skrzypski M,Jassem J

    更新日期:2018-05-01 00:00:00

  • PD-1 and PD-L1 blockade in gastrointestinal malignancies.

    abstract::Immunotherapy represents a major breakthrough in cancer therapy in recent years. Immune-checkpoint blockade using PD-1 and PD-L1 antibodies appears to be one of the most promising immunotherapy approaches. Immunotherapy differs from conventional cancer treatment because of its ability to produce durable responses in s...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.09.004

    authors: Lote H,Cafferkey C,Chau I

    更新日期:2015-12-01 00:00:00

  • DNA repair and cancer stem-like cells--potential partners in glioma drug resistance?

    abstract::Glioblastoma is the most malignant and frequent primary brain tumour in adults. Current treatment remains insufficient as these tumours display a diffuse infiltrative growth pattern and tend to recur despite extensive debulking surgery followed by radio- and chemotherapy. The alkylating agents carmustine (1,3-bis-(2-c...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2008.03.125

    authors: Johannessen TC,Bjerkvig R,Tysnes BB

    更新日期:2008-10-01 00:00:00

  • Cancer surgery: the last 25 years.

    abstract::Surgery is, and always has been, the main treatment modality of solid tumours. For a long period, it consisted of a number of surgical procedures dictated by basic oncologic principles, most of which are still adhered to. Over the last few decades, increased understanding of the disease, new or improved diagnostic fac...

    journal_title:Cancer treatment reviews

    pub_type: 历史文章,杂志文章,评审

    doi:10.1053/ctrv.1999.0147

    authors: Bremers AJ,Rutgers EJ,van de Velde CJ

    更新日期:1999-12-01 00:00:00

  • A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.

    abstract:BACKGROUND:To provide an updated review of adverse events associated with sunitinib, pazopanib, bevacizumab, temsirolimus, axitinib, everolimus and sorafenib and their management. MATERIALS AND METHODS:We performed a PubMed and Cochrane-based review of side effects associated with the seven agents including product mo...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/j.ctrv.2012.12.006

    authors: Alasker A,Meskawi M,Sun M,Ismail S,Hanna N,Hansen J,Tian Z,Bianchi M,Perrotte P,Karakiewicz PI

    更新日期:2013-06-01 00:00:00

  • Open conservation partial laryngectomy for laryngeal cancer: a systematic review of English language literature.

    abstract:BACKGROUND:Different modalities of treatment in early laryngeal cancer lead to equivalent oncological outcomes. Hence this systematic review was undertaken to synthesise the key oncological outcomes following primary open partial laryngectomy for laryngeal cancer. METHODS:A systematic review of the English literature ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2011.05.010

    authors: Thomas L,Drinnan M,Natesh B,Mehanna H,Jones T,Paleri V

    更新日期:2012-05-01 00:00:00

  • Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination.

    abstract::Microtubule stabilization by chemotherapy is a powerful weapon in the war against cancer. Disruption of the mitotic spindle activates a number of signaling pathways, with consequences that may protect the cell or lead to its death via apoptosis. Taxol, the first microtubule stabilizing drug to be identified, has been ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2006.01.004

    authors: Bergstralh DT,Ting JP

    更新日期:2006-05-01 00:00:00

  • DNA-based drug interactions of cisplatin.

    abstract::The interactions of cisplatin with other anti-cancer agents on the DNA level have been studied extensively in pre-clinical experiments. In general, combination of cisplatin with an antimetabolite, taxane, or topoisomerase inhibitor, can result in a modulation of platinum pharmacology on the DNA, for example, enhanced ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(02)00093-2

    authors: Crul M,van Waardenburg RC,Beijnen JH,Schellens JH

    更新日期:2002-12-01 00:00:00

  • Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer.

    abstract::The chemo-immunotherapy (CIT) and chemo-adoptive immunotherapy (CAIT) regimens tested in the past decade are summarized. From them we have learned a great deal about the interactions between various chemotherapeutic agents, immune modulating agents and effector cells. The most commonly reported result in multi-modalit...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1053/ctrv.2001.0222

    authors: Gomez GG,Hutchison RB,Kruse CA

    更新日期:2001-12-01 00:00:00

  • The Notch-1 receptor in prostate tumorigenesis.

    abstract::The Notch signalling pathway plays a fundamental role in tissue development due to its involvement in cell fate determination and postnatal tissue differentiation. Its capacity to regulate cell growth and development has been linked to the occurrence of several cancers including that of the prostate. The transmembrane...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2017.04.003

    authors: O'Brien R,Marignol L

    更新日期:2017-05-01 00:00:00

  • The role of bone markers in metastatic bone disease.

    abstract::Patients with advanced cancer often develop bone metastases that lead to significant skeletal morbidity and substantially reduced functionality and autonomy [Coleman RE, Rubens RD. Bone metastases. In: Clinical Oncology, 2nd edn. New York: Churchill Livingstone. 2004, p. 1091-128]. As current methods of diagnosing bon...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(06)80001-0

    authors: Coleman RE

    更新日期:2006-01-01 00:00:00

  • The sentinel node negative axilla: is it a no-go zone?

    abstract::The technique of sentinel node biopsy (SNB) presents a great opportunity to reduce the morbidity of surgical treatment of breast cancer. Using either dye, isotope or a combination, after completing a learning process a sensitivity of 80-99% may be achieved. Most surgeons would aim for a sensitivity of 95% but this wil...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1053/ctrv.2002.0251

    authors: Fentiman IS,Mansel RE

    更新日期:2002-02-01 00:00:00